MARINUS PHARMACEUTICALS, INC. financial data

Location
Radnor, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 12 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 283% % -66%
Quick Ratio 13% % 139%
Debt-to-equity -503% % -374%
Return On Equity 494% %
Return On Assets -122% % -103%
Operating Margin -396% % 2.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55,185,622 shares 1.1%
Common Stock, Shares, Outstanding 55,185,622 shares 1.1%
Common Stock, Value, Issued $55,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 57,229,229 shares 6.1%
Weighted Average Number of Shares Outstanding, Diluted 57,229,229 shares 6.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $31,466,000 USD 1.6%
Research and Development Expense $87,731,000 USD -7.1%
Costs and Expenses $156,040,000 USD -0.12%
Operating Income (Loss) $124,574,000 USD 0.55%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $24,225,000 USD 27%
Net Income (Loss) Attributable to Parent $140,491,000 USD -4.9%
Earnings Per Share, Basic -2 USD/shares 10%
Earnings Per Share, Diluted -2 USD/shares 8.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $42,184,000 USD -70%
Cash, Cash Equivalents, and Short-term Investments $113,300,000 USD
Accounts Receivable, after Allowance for Credit Loss, Current $3,840,000 USD -10%
Inventory, Net $6,717,000 USD 146%
Assets, Current $57,401,000 USD -71%
Property, Plant and Equipment, Net $4,882,000 USD 25%
Operating Lease, Right-of-Use Asset $500,000 USD -50%
Other Assets, Noncurrent $1,341,000 USD -28%
Assets $63,624,000 USD -68%
Accounts Payable, Current $3,707,000 USD 41%
Employee-related Liabilities, Current $2,129,000 USD -70%
Accrued Liabilities, Current $14,159,000 USD -23%
Liabilities, Current $34,504,000 USD 13%
Operating Lease, Liability, Noncurrent $211,000 USD -79%
Liabilities $130,364,000 USD -11%
Retained Earnings (Accumulated Deficit) $670,648,000 USD -26%
Stockholders' Equity Attributable to Parent $66,740,000 USD -222%
Liabilities and Equity $63,624,000 USD -68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $37,461,000 USD 9.7%
Net Cash Provided by (Used in) Financing Activities $257,000 USD
Net Cash Provided by (Used in) Investing Activities $20,885,000 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 55,192,929 shares 1.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,319,000 USD 83%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42,184,000 USD -70%
Interest Paid, Excluding Capitalized Interest, Operating Activities $2,671,000 USD 24%
Operating Lease, Liability $804,000 USD -47%
Depreciation $131,000 USD -17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $140,420,000 USD -4.8%
Lessee, Operating Lease, Liability, to be Paid $853,000 USD -49%
Operating Lease, Liability, Current $804,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year One $642,000 USD -24%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $49,000 USD -73%
Additional Paid in Capital $603,853,000 USD 3.3%
Share-based Payment Arrangement, Expense $18,865,000 USD 20%
Interest Expense $17,094,000 USD 30%